Nabriva Therapeutics: Falls on pricing 6 mln share offering
11/12/2020 09:45
** Antibiotic maker's NBRV.O shares down 25.29% at $2.54
premarket, among top losers on Nasdaq
** Co announced pricing of 6 mln-share offer at $2.50 per
share, a 26.47% discount to NBRV's last close urn:newsml:reuters.com:*:nGNXyDjx1
** Gross proceeds of $15 mln expected from offering - NBRV
** Co says offering expected to close on or about Dec. 15
** H.C. Wainwright & Co exclusive placement agent for
offering
** Up to Thursday's close, stock down 74.24% YTD
(Reporting by Rithika Krishna)
((Rithika.Krishna@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update